Docetaxel News and Research

RSS
Docetaxel is approved by the Food and Drug Administration (FDA) to be used alone or with other drugs to treat certain types of breast and non-small cell lung cancer (NSCLC). It is also approved to be used with other drugs to treat squamous cell carcinoma of the head and neck (SCCHN) and certain types of gastric and prostate cancer.

Docetaxel is a semi-synthetic, second-generation taxane derived from a compound found in the European yew tree Taxus baccata. Docetaxel displays potent and broad antineoplastic properties; it binds to and stabilizes tubulin, thereby inhibiting microtubule disassembly which results in cell- cycle arrest at the G2/M phase and cell death. This agent also inhibits pro-angiogenic factors such as vascular endothelial growth factor (VEGF) and displays immunomodulatory and pro-inflammatory properties by inducing various mediators of the inflammatory response. Docetaxel has been studied for use as a radiation-sensitizing agent.
Molecular fingerprint of breast cancer drug resistance can predict response to treatment

Molecular fingerprint of breast cancer drug resistance can predict response to treatment

Some cancer cells mimic stem cells to evade chemotherapy

Some cancer cells mimic stem cells to evade chemotherapy

New algorithm matches any tumor cells to best possible anti-cancer treatments

New algorithm matches any tumor cells to best possible anti-cancer treatments

Latest drugs improve survival for metastatic breast cancer

Latest drugs improve survival for metastatic breast cancer

Abiraterone reduces levels of prostate specific antigen

Abiraterone reduces levels of prostate specific antigen

C-reactive protein identified as marker for prostate cancer survival

C-reactive protein identified as marker for prostate cancer survival

Oncolytic viruses deliver a knockout punch to cancers

Oncolytic viruses deliver a knockout punch to cancers

Viventia Biotech announces results of Proxinium antibody in combinaton with chemotherapy and radiation

Viventia Biotech announces results of Proxinium antibody in combinaton with chemotherapy and radiation

OncoGenex Technologies announces data from a Phase II clinical trial of OGX-011

OncoGenex Technologies announces data from a Phase II clinical trial of OGX-011

Cell Genesys reports data from clinical trials of GVAX immunotherapy for prostate cancer

Cell Genesys reports data from clinical trials of GVAX immunotherapy for prostate cancer

New chemical agent, MCP110, provides synergistic effect to standard drugs

New chemical agent, MCP110, provides synergistic effect to standard drugs

Scientists link treatment-induced growth factor to cancer spread

Scientists link treatment-induced growth factor to cancer spread

Inhaled Celecoxib shows new promise for lung cancer treatment

Inhaled Celecoxib shows new promise for lung cancer treatment

New understanding of how and why Taxol works in patients with breast cancer

New understanding of how and why Taxol works in patients with breast cancer

FDA approves Taxotere for head and neck cancers

FDA approves Taxotere for head and neck cancers

Txr1 gene that affects human cancer cells' sensitivity to chemotherapy

Txr1 gene that affects human cancer cells' sensitivity to chemotherapy

Few well performed studies address management of lymph node positive prostate cancer

Few well performed studies address management of lymph node positive prostate cancer

Radionuclide therapy with chemotherapy effective in treating prostate cancer

Radionuclide therapy with chemotherapy effective in treating prostate cancer

Advanced prostate cancer can be treated successfully with intermittent chemotherapy

Advanced prostate cancer can be treated successfully with intermittent chemotherapy

Taxotere combined with standard chemotherapy improves survival in advanced head and neck cancers

Taxotere combined with standard chemotherapy improves survival in advanced head and neck cancers

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.